From past to present: tracing the trends of diabetes drug trials in mainland China
China has made significant advancements in diabetes drug research and development over the past decade. However, problems such as serious drug homogeneity, and insufficient innovation have become increasingly prominent. The government, clinical trial institutions, and pharmaceutical companies must collaborate to promote the high-quality development of drug clinical trials.
Authors
- Hongjun Shi
- Zengqing Ma
- Susu Li
- Hong Zhang (ORCID: https://orcid.org/0000-0002-4084-5150)
- Yu Lin
- Lianping Wu
- Xin Zhao (ORCID: https://orcid.org/0000-0003-1828-4577)
- Tao Yang (ORCID: https://orcid.org/0000-0003-3996-1477)
Institutions
- Gaochun People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3389/fendo.2024.1427148
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.00